MultiCell Technologies works on cancer drug

LINCOLN – MultiCell Technologies Inc. says it has reached a milestone in its work to develop a drug to treat colorectal cancer, the third leading cause of death from cancer among both men and women in the United States. MCT-475 is a patent-pending antigen presenting immunoglobulin therapeutic to be co-administered with MCT-465, another MultiCell drug.…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -